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Insulin and Risk of Cardiovascular Disease
A Meta-Analysis
J.B. Ruige, MD; W.J.J. Assendelft, MD, PhD; J.M. Dekker, PhD; P.J. Kostense, PhD;
R.J. Heine, MD, PhD; L.M. Bouter, PhD
Background—Our purposes were to estimate the strength of the longitudinal relationship between hyperinsulinemia and
cardiovascular diseases (CVD) from the available literature and to identify study characteristics that modify this relationship.
Methods and Results—Articles were identified by means of a MEDLINE and Embase search and citation tracking. Eligible
studies were prospective population-based cohort studies and nested case-control studies on the relationship between, on
the one hand, fasting or nonfasting insulin levels and, on the other hand, myocardial infarction, death from coronary heart
disease, and/or ECG abnormalities. Data were extracted pertaining to insulin measurements, type of outcome studied,
adjustment for confounding, sex, mean age of the study population, follow-up period, insulin assay, and ethnic background
(white or nonwhite). Associations of insulin and CVD were reexpressed in a uniform manner, an estimate of relative risk
(RR) and 95% CI, to be used in meta–regression analyses. Twelve of 17 potentially eligible articles provided sufficient
information. Overall, a weak positive association was found. The meta-analysis resulted in an estimated summary RR (95%
CI) of 1.18 (1.08 to 1.29) for differences in insulin level, equivalent to the difference between the 75th and the 25th
percentiles of the general population in the Netherlands. Ethnic background and type of insulin assay modified the
relationship between insulin and CVD with borderline significance.
Conclusions—Hyperinsulinemia is a weak risk indicator for the occurrence of CVD. The relationship between hyperinsu-
linemia and CVD was modified by ethnic background and by the type of insulin assay involved. (Circulation.
1998;97:996-1001.)
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The effect of hyperinsulinemia on the occurrence of cardio-vascular disease (CVD) has been studied in various large
prospective studies but, as yet, no unequivocal relationship has
been established.1,2 It is known that hyperinsulinemia precedes
type II diabetes and that it is associated with an adverse
cardiovascular risk profile. Type II diabetes carries a strongly
increased risk for CVD, but the role of hyperinsulinemia itself
in this process is not clear.3 Recent articles4–6 suggest that
hyperinsulinemia reflects a compensatory mechanism of de-
creased insulin sensitivity of the peripheral tissues to insulin.
This “insulin resistance” might be essential in the pathogenesis
of CVD and of type II diabetes.7 At the moment, ongoing
epidemiological studies investigating this mechanism are di-
rected toward measuring specific levels of insulin and insulin
resistance.8,9 Nevertheless, sources of the heterogeneity that
could explain earlier conflicting results remain obscure.10
Previous reviews on this issue1–5 have been narrative in nature.
Therefore, we decided to perform a meta-analysis to estimate
the strength of the longitudinal relationship between hyperin-
sulinemia and CVD and to identify study characteristics that
modify this relationship.
Methods
Eligible Articles
Articles were identified by means of an Index Medicus (MEDLINE)
and Embase search and by citation tracking covering the period 1966
to 1996. Key words were insulin, prospective, cohort, follow-up,
cardiovascular, myocardial infarction, and electrocardiography. Eligi-
ble for inclusion were, on the one hand, prospective population-based
cohort studies and nested case-control studies on insulin levels and, on
the other hand, myocardial infarction, death from coronary heart
disease, and/or ECG abnormalities. Data were extracted pertaining to
fasting and nonfasting insulin levels, type of outcome studied (myo-
cardial infarction, death from coronary heart disease, ECG abnormal-
ities), confounders for which adjustment was made, sex, mean age of
the study population, follow-up period, type of insulin assay involved,
and ethnic background (white or nonwhite). If researchers presented
different follow-up periods on the same study population, the study
with the follow-up period closest to the mean of the other study
populations in the meta-analysis was selected. Articles had to provide
enough information to estimate a relative risk (RR) and a 95% CI or
an approximation, such as an odds ratio. We abstracted the estimated
RR, adjusted for the highest number of potentially confounding
variables, from each of the original articles.
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Standardization of Study-Specific Associations
The objectives of this meta-analysis were to obtain a summary
estimate of the effect of hyperinsulinemia on CVD and to explore
sources of heterogeneity among the RRs of the various studies.
Analyses were performed separately for fasting and nonfasting insulin
levels. Most studies provided fasting as well as nonfasting insulin levels,
but only one association per study population could be used per
analysis. This stratified analysis therefore prevented arbitrary choices
from being made but made it possible to investigate the differences in
RRs for fasting and nonfasting insulin levels. We obtained the
summary estimate across the different study populations by first
estimating a coefficient (b) that represented the relationship between
insulin and CVD per study and subsequently estimating a weighted
average of the coefficients. The weight of each study was calculated
inversely to the variance estimate of the coefficient after reexpression
of the SE in a uniform manner.11 For cohort and nested case-control
studies, the b represents the coefficient for the effect of one standard
unit difference (to be specified) in insulin level in a Cox proportional
hazards, logistic regression, or Poisson regression model.12 The reex-
pressed RR of cardiovascular disease per specified uniform difference
in insulin level is therefore exp(b), assuming that the RR is constant
during follow-up and the absolute risk is small. In the same manner,
the 95% CI can be calculated as exp(b61.96 SE). For studies that did
not directly supply data that allowed the calculation of b and its SE, the
computation methods described by Greenland were used.11 This
calculation of the RRs (95% CI) shows a relative risk for a difference
of 50 pmol/L (fasting insulin levels) or 250 pmol/L (nonfasting insulin
levels). This approximates the difference between the 75th and the
25th percentiles in the 50- to 74-year-old general population in the
Netherlands13 for fasting and nonfasting insulin levels, respectively. If
a study provided an RR without sufficient specification of the
difference in insulin levels involved, tables and figures from the same
article were used to estimate the difference in insulin levels at issue.
Articles from the Kuopio study14 and the Busselton study15 did not
provide enough information in tables and figures to identify the
difference in insulin level for which the RRs were calculated.
Therefore, data on insulin distribution in a Dutch general population
was used to estimate the difference in insulin levels that the RR refers
to in the Kuopio study. We postulated that the distributions of the two
populations were similar, because mean insulin levels of the Dutch
population13 and the Kuopio study14 were very similar. In the same
way, data from the Helsinki study16 were used to estimate the
difference in insulin levels for the RR of the Busselton study.15 The
latter studies had in common that they measured insulin levels 1 hour
after an oral glucose tolerance test. Sensitivity analyses were performed
to evaluate the influence of these estimations on the final
conclusions.17
Sources of Heterogeneity and
Summary Estimates
Univariate and multivariate meta–regression analyses were used to
identify study characteristics that could explain differences in the
relationship between insulin and CVD.11,18 With this approach, the
logarithm of the study RR is regressed on study characteristics of
interest. Fixed-effect linear regression models were fitted by weighted
least squares.11 The fit of the weighted regression model was evaluated
by comparing the residual sum of squares to a x2 distribution.11,19 A
small probability value indicates a poor fit. The importance of various
study characteristics was evaluated according to the size of the b value
as well as its CI. Subsequently, summary estimates for the effect of
hyperinsulinemia on CVD were provided, stratified according to the
study characteristics that significantly modified the relationship. The
importance of study characteristics identified by meta–regression
analyses was confirmed by two different meta-analytic techniques:
first, heterogeneity tests of pooled studies, of which small values of P
indicate differences in the RRs (95% CI) of these studies,11 and
second, summary RRs (95% CI) of pooled studies, calculated accord-
ing to fixed- as well as random-effects models.20,21 Summary RRs
(95% CI) calculated by fixed-effects models imply that differences in
the RRs (95% CI) of pooled studies are due to sampling error.
Summary RRs (95% CI) calculated according to random-effects
models make allowance for unidentified sources of heterogeneity
beyond sampling error.21 This incorporation of possible unidentified
sources of heterogeneity in the random-effects models results, in
general, in a greater contribution of smaller studies to the overall mean
in the random-effects models than in the fixed-effects models.
Differences between summary RRs (95% CI) calculated according to
both models indicate unidentified sources of heterogeneity, in which
case the RR (95% CI) of the random-effects model is the more
appropriate. Otherwise, only RRs (95% CI) of the fixed-effects model
are presented.20,21 Study characteristics that were consecutively in-
cluded in meta-regressions as possible sources of heterogeneity were
the type of outcome studied (myocardial infarction and death from
coronary heart disease and/or ECG abnormalities), adjustment for
confounding (both the number of confounding variables and the
presence or absence of control for a specific confounder), sex (male
versus female or mixed population), mean age of the study population,
length of follow-up period, insulin assay (specific insulin assay versus
potential cross-reactivity with proinsulin-like molecules), and ethnic
background (white versus nonwhite). Analyses were performed with
the SPSS-PC software package, version 5.0.
Results
Twenty-two potentially eligible articles with data on insulin
levels and CVD were identified.14–16,22–40 Twelve articles de-
scribing 17 different studies were included in the meta–
regression analyses and are listed in Table 1.14,15,22–28,30,34,39 The
coefficient, corresponding SE, and unit increment (specified
difference in insulin level) derived from the original articles,
before reexpression, are shown. Subsequently, RRs and 95%
CIs are presented, after reexpression for a difference of 50
pmol/L fasting or 250 pmol/L nonfasting insulin. The Bussel-
ton,15 Helsinki,16,23 and British Regional Heart27 studies pro-
vided data on different follow-up periods of the same study
populations. One study per population was chosen, the closest
to the mean follow-up period of the remaining studies.
Sensitivity analyses revealed that using a study on any of the
other reported follow-up periods had no substantial influence
on the final conclusions17 (data not shown). Eleven articles did
not provide sufficient quantitative information for this meta-
analysis. Two studies30,34 could be included after additional
details were provided by direct correspondence and are listed
in Table 1. Five articles described study populations that had
already been included,35–38,40 and 4 other articles are listed in
Table 2.29,31–33 Of these 4 articles, 1 found a negative association
between hyperinsulinemia and CVD,32 and 3 did not find an
association.29,31,33
Overall, this meta-analysis showed weak positive associa-
tions between insulin levels and CVD. An increase of 50
pmol/L fasting insulin resulted in a summary RR (95% CI) of
1.18 (1.08 to 1.29) before stratification (Table 3). However,
the meta-analyses revealed heterogeneity across studies of
nonfasting insulin and CVD (probability value of heterogene-
ity test, P5.007, Table 3). The heterogeneity might be
explained by a difference between studies involving white and
nonwhite populations. Separate summary RRs were 1.04
(0.93 to 1.16) for studies of nonwhite populations and 1.42
(1.23 to 1.65) for studies of white populations, respectively.
Unfortunately, it was not possible to identify the study
characteristic responsible for this heterogeneity, because ethnic
background, mean age of study population, and the type of
outcome studied were highly correlated within these studies.
Ruige et al 997
 at Vrije on July 4, 2011 circ.ahajournals.orgDownloaded from 
All studies of nonwhite populations had younger subjects and
used only ECG abnormalities as outcome, in contrast to studies
of white populations, which had older subjects and used
clinical myocardial infarction or death from coronary heart
disease as outcome (exception: see Reference 28). Another
source of heterogeneity across studies, identified with meta-
regression analyses, was the type of insulin assay involved.
Although the probability value of the heterogeneity tests
(P5.09, fasting studies in whites; P5.11, nonfasting studies in
whites; Table 3) does not confirm strongly that this study
TABLE 1. Summary of Results of Prospective Studies Included in Meta–Regression Analyses of Insulin and
Cardiovascular Disease
Study (Reference)
Time (h)
Insulin
After OGTT
Follow-up
Period, y Outcome
No. of
Patients
Original Coefficient (SE)*
RR (95% CI) After
Reexpression†Increment
Coefficient
(b) SE
Studies in whites
Helsinki study23‡ . . . 9.5 MD 63 U20/L80 0.216 0.138 1.35 (0.93-1.97)
Paris study24§ . . . 10 D 126 U20/L80 0.604 0.308 1.58 (1.00-2.49)
Kuopio study14‡ . . . 3.5 MD 74 U20/L80 0.182 0.311 1.08 (0.83-1.40)
Quebec C study28‡\ . . . 5 MDE 91 1 SD 0.470 0.188 2.31 (1.20-4.46)
Edinburgh study30‡¶ . . . 12 MD 11 . . . . . . . . . 1.18 (0.92-1.51)
Danish study39§ . . . 17 MD 123 1 mU/L 0.029 0.010 1.27 (1.08-1.49)
MRFIT study34‡\¶ . . . 7-10 MD 208 mU/mL 20.12 0.179 1.01 (0.35-1.19)
Busselton study15 1 6 MD 114 U20/L80 0.513 0.199 1.41 (1.08-1.83)
Helsinki study23‡ 2 9.5 MD 63 U20/L80 0.352 0.119 1.80 (1.22-2.65)
Paris study25§ 2 15 D 174 U20/L80 0.438 0.169 1.30 (1.06-1.59)
British RH study27§ Nonfasting 11.5 MD 520 U10/L90 0.470 0.188 5.31 (1.43-19.7)
Studies in nonwhites
Nauru study (female)22‡ . . . 5 E 13 1 mU/mL 0.009 0.032 1.09 (0.64-1.84)
Nauru study (male)22‡ . . . 5 E 6 1 mU/mL 0.030 0.022 1.27 (0.88-1.83)
Pima indian study26§ . . . 6.7 E 16 U10/L10 0.833 0.452 1.15 (0.99-1.34)
Nauru study (female)22‡ 2 5 E 14 1 mU/mL 0 0.003 1.00 (0.76-1.31)
Nauru study (male)22‡ 2 5 E 6 1 mU/mL 20.002 0.006 0.92 (0.53-1.59)
Pima indian study26§ 2 6.7 E 16 U10/L10 0.419 0.511 1.05 (0.93-1.19)
OGTT indicates oral glucose tolerance test; M, myocardial infarction; D, death from coronary heart disease; and E, ECG abnormalities.
*Coefficient per increment (specified difference in insulin level) derived from the original article, adjusted by confounding variables mentioned in Table 4, but before
reexpression, eg, a coefficient of 0.51 per U20/L80 is a coefficient of 0.51 for subjects with the highest 20% vs the lowest 80% of insulin levels.
†Relative risk (RR) and 95% CI after reexpression for a difference of 50 pmol/L fasting insulin or 250 pmol/L nonfasting insulin.
‡Logistic regression analysis.
§Cox regression analysis.
\Nested case-control studies.
¶RR (95% CI) obtained by direct correspondence with the authors.
TABLE 2. Summary of Results of Prospective Studies Not Included in Meta–Regression Analyses of Insulin and
Cardiovascular Disease
Study (Reference)
Time (h)
Insulin
After OGTT
Follow-up
Period, y Outcome
No. of
Patients
Original Coefficient (SE)* Original Mean (SD)
Increment Coefficient (b) SE Cases Noncases Units
Studies in whites
Study of men born in 191329‡ . . . 8 MD 66 14.6 (9.0) 13.0 (8.8) mU/L
San Luis Valley study31† . . . 4 M 72
Caerphilly study33‡\ . . . 5 MD 113 1 SD 0.039 0.109 6.53 (6.7) 5.69 (5.9) mU/L
Rancho Bernardo study32§ 2 5 D 22 1 SD 20.357 0.210 39.7 59.4 mU/mL
Abbreviations as in Table 1.
*Original coefficient (SE) as provided in the article, adjusted by confounding variables mentioned in Table 4. Reexpression of the association is not possible because the
increment (specified difference in insulin level, eg, 1 SD) was expressed on a logarithmic scale.
†In the San Luis Valley Diabetes Study, no association was found (abstract).
‡Logistic regression.
§Cox regression analysis.
\Nested case-control study.
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characteristic induces heterogeneity, meta–regression analyses
are generally regarded to be more sensitive in revealing sources
of heterogeneity.11 In the fasting and nonfasting studies, only
one study involved a specific insulin assay, and they both had
higher RRs. Again, however, interference with other study
characteristics could not be excluded. One of the studies27
measured nonfasting insulin without using an oral glucose
tolerance test, and the other28 had a nested case-control design.
A study that involved a nonspecific insulin assay and nested
case-control design had a population selection of middle-aged
men with a high-risk profile.34 Adjustment for confounding
varied greatly across studies for both type and number for
which adjustment was made, as is shown in Table 4. In general,
most studies adjusted only for a limited number of confound-
ers. More than nine studies adjusted for age, body mass index,
smoking, blood pressure, glucose level, cholesterol, and tri-
glycerides. In our meta-regression, neither the number of
confounding variables for which adjustment was made, the
presence or absence of control for one specific confounder,
length of follow-up period, nor sex differences in the study
populations modified the association between insulin and
CVD.
Discussion
In contrast to previous narrative reviews,1–5 this meta-analysis
provides a quantitative estimate of the strength of the longi-
tudinal relationship between insulin and CVD and systemati-
cally investigates which study characteristics could be respon-
sible for the heterogeneity of this relationship. The overall
relationship between insulin and CVD turned out to be weak,
and ethnic background as well as type of insulin assay involved
were identified as potentially important study characteristics.
The strength of the relationship was therefore presented for the
different categories of these characteristics. However, both
ethnic background and type of insulin assay involved were
correlated to other study characteristics, and this might also be
a cause of the modification effect. Thus, definite conclusions
cannot yet be made on the basis of this meta-analysis alone,41
but it stresses the importance of further research on these issues.
Another remarkable finding was the great variety across studies
in the number and type of confounding variables for which
adjustment was made. Although the absolute number of
confounders adjusted for in the individual studies does not
appear to be a modifier of the relationship between insulin and
CVD, more research into the role of individual confounders or
intermediates is also clearly needed.2 The ability of this
meta-analysis to identify important study characteristics was
limited by the fact that some investigators adjusted for a
particular study characteristic of interest, whereas other inves-
tigators excluded the same study characteristic by design (eg,
sex, glucose intolerance). In future, a more uniform approach
would facilitate meta–regression analyses to identify sources of
heterogeneity and thus contribute to insight into pathogenic
mechanisms.
The question of whether insulin itself increases the risk for
CVD, independent of insulin resistance, cannot be answered
by this meta-analysis, because none of the included studies
measured both insulin and insulin resistance. Cross-sectional
results of the IRAS study, in which insulin levels and insulin
resistance both were measured in '1400 subjects, did not
show an independent association between insulin level and
CVD.9 A recent experimental study also found no evidence of
a role of exogenous insulin in accelerating atherosclerosis.42
The importance of ethnic background for the pathogenic
mechanism is suggested by studies showing a stronger longi-
tudinal relationship in white than in nonwhite populations. In
studies of nonwhite populations, however, the outcome
(CVD) was assessed only by means of electrocardiography, and
the mean age of the study population was generally lower.
ECG abnormalities reflect ischemia or previous myocardial
infarction, whether or not clinically manifest, but obviously
they do not reflect sudden coronary heart death. Clinical
myocardial infarction and coronary heart death, by definition,
reflect CVD. Theoretically, it is possible that the pathophysi-
ology involved might be slightly different between these two
outcomes. Pooling individual patient data from different stud-
ies would probably not reveal the responsible determinant
either, because in various studies the distribution of determi-
nants is highly influenced by the study design, resulting in an
unresolved correlation between determinants.14,22–28,39 Ethnic
background as a modifier is further supported by the previously
mentioned IRAS study9 and by a discrepancy between low
TABLE 3. Meta-Analysis of Relationship Between Insulin and Cardiovascular Disease
Studies No.
Fixed-Effects Model
RR (95% CI)
Random-Effects Model
RR (95% CI)*
P Value of
Heterogeneity Test
All fasting insulin studies 10 1.17 (1.09-1.26) 1.18 (1.08-1.29) .27
Studies in nonwhites 3 1.16 (1.02-1.33) .84
Studies in whites 7 1.18 (1.08-1.29) 1.21 (1.06-1.39) .09
Nonspecific insulin assay 6 1.16 (1.06-1.27) .24
Specific insulin assay 1 2.31 (1.20-4.46) . . .
All nonfasting insulin studies 7 1.16 (1.06-1.27) 1.25 (1.03-1.51) .007
Studies in nonwhites 3 1.04 (0.93-1.16) .87
Studies in whites 4 1.42 (1.23-1.65) 1.43 (1.23-1.66) .11
Nonspecific insulin assay 3 1.40 (1.21-1.62) .34
Specific insulin assay 1 5.31 (1.43-19.7) . . .
Summary relative risks (RRs) are provided for a difference of 50 pmol/L fasting insulin or 250 pmol/L nonfasting insulin.
*Random-effects model RRs (95% CI) are provided only in cases of differences from fixed-effects model RRs (95% CI).
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rates of CVD and high rates of non–insulin-dependent diabetes
mellitus in Pima Indians.43 In our study, the type of insulin
assay involved turned out to be another potentially important
modifier. In contrast to expectations, studies with a specific
insulin assay27,28 had a high RR, despite recent findings that
showed the importance of proinsulin and split products in
accelerating atherosclerosis.44,45 Again, correlation with other
study characteristics made it impossible to draw definite
conclusions on this issue. In future research, however, detailed
measurements of specific insulin, proinsulin, and insulin-like
molecules with specific assays44,45 are needed, as well as specific
measurements of insulin resistance.
This meta-analysis is based on a limited number of articles,
of which a substantial proportion provided insufficient infor-
mation. A few articles provided means (and SDs) of cases and
controls to show the relationship between insulin and CVD.
Unfortunately, procedures to estimate RRs (with 95% CI)
from means (and SDs) for these studies could not be per-
formed, because insulin distributions are typically highly
skewed.11 Except for the MRFIT34 and the Edinburgh study,30
an attempt to gather additional information from these studies
by direct correspondence with the authors provided no addi-
tional ways of calculating RRs. Another limitation was “pre-
sentation bias,” ie, some articles provided more information on
statistically significant than on statistically nonsignificant asso-
ciations. For example, although the relevant data were collect-
ed,25 the “15-year follow-up” article of the Paris Prospective
Study did not provide enough information on the nonsignif-
icant association between fasting insulin and CVD to reexpress
the RR (95% CI). A more general limitation in review of the
literature is that it is prone to publication bias. We explicitly
investigated this by plotting the number of cases versus effect
magnitude, which resembled a funnel,46 indicating the relative
absence of publication bias (data not shown). Estimates with a
small sample size were spread out over a wide range, and
estimates with a large sample size were spread out over a
smaller range; no discontinuity could be found. Publication
bias might be limited for the above-mentioned topic, because
in this area negative as well as positive results are generally
considered to be clinically relevant.7 In the meta-analysis, no
assessment of the methodological quality of the studies was
made, because this is highly arbitrary.21,47,48
The advantage of this meta-analysis is that it clearly identifies
sources that could potentially modify the relationship between
insulin and CVD. Moreover, it reveals issues that vary greatly
between studies (eg, number and type of confounding or inter-
mediate variables) or are in need of improvement (eg, correct
presentation of significant as well as nonsignificant data). In
TABLE 4. Summary of Confounding Variables Adjusted for in Prospective Studies on Insulin and Cardiovascular Disease
Confounding Variables
Table 1 (Included in Meta–Regression Analyses)
Table 2 (Not
Included)
Whites Nonwhites Whites
Reference 23 24 14 28* 30† 39 36* 15 23 25 27 22 26 22 26 29 31 33* 32
Time (h) insulin after OGTT . . . . . . . . . . . . . . . . . . . . . 1 2 2 n-f . . . . . . 2 2 . . . . . . . . . 2
Prevalent CVD z z
Age z z z z z z z z z z z z
Sex z z z z
Body mass index z z z z z z z z z z
Waist-to-hip ratio z
Physical activity z z z z z
Smoking z z z z z z z z z z z
Alcohol consumption z z z z
Forced expiratory volume z
Social class z
Blood pressure z z z z z z z z z z
Antihypertensive therapy z z z
Glucose z z z z z z z z z z
Cholesterol z z z z z z z z z
HDL cholesterol z z z z z z
LDL cholesterol z z
Triglycerides z z z z z z z z z z
Heart rate z
Uric acid z z
Apolipoprotein B z
Family history CVD z
OGTT indicates oral glucose tolerance test; n-f, nonfasting; and CVD, cardiovascular disease.
*Nested case-control study.
†Information obtained by direct correspondence with the authors.
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conclusion, both fasting and nonfasting hyperinsulinemia seem to
be weak risk indicators for the occurrence of CVD. Sources that
could potentially modify the relationship between insulin and
CVD are ethnic background and type of insulin assay.
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